What’s Ahead for Avenue Therapeutics Inc (NASDAQ:ATXI) After Less Shorted Shares?

March 18, 2018 - By Peter Erickson

 What’s Ahead for Avenue Therapeutics Inc (NASDAQ:ATXI) After Less Shorted Shares?

The stock of Avenue Therapeutics Inc (NASDAQ:ATXI) registered a decrease of 75% in short interest. ATXI’s total short interest was 700 shares in March as published by FINRA. Its down 75% from 2,800 shares, reported previously. The short interest to Avenue Therapeutics Inc’s float is 0.01%.

The stock increased 2.00% or $0.11 during the last trading session, reaching $5.6. About 18,498 shares traded. Avenue Therapeutics, Inc. (NASDAQ:ATXI) has 0.00% since March 18, 2017 and is . It has underperformed by 16.70% the S&P500.

Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes an intravenous formulation of tramadol HCI principally for use in the acute/intensive care hospital setting. The company has market cap of $57.49 million. The Company’s product candidate is IV Tramadol for the treatment of post-operative pain. It currently has negative earnings. The firm was founded in 2015 and is based in New York, New York.

More notable recent Avenue Therapeutics, Inc. (NASDAQ:ATXI) news were published by: Globenewswire.com which released: “Avenue Therapeutics Completes Initial Public Offering” on June 30, 2017, also Globenewswire.com with their article: “Avenue Therapeutics to Present at March Investor Conferences” published on March 05, 2018, Reuters.com published: “BRIEF-Avenue Therapeutics ic files for IPO of up to $50 mln” on May 22, 2017. More interesting news about Avenue Therapeutics, Inc. (NASDAQ:ATXI) were released by: Globenewswire.com and their article: “Avenue Therapeutics Receives Notice of Allowance for a New Patent Application …” published on May 19, 2017 as well as Globenewswire.com‘s news article titled: “Avenue Therapeutics Announces Appointment of Joseph Vazzano as Vice President …” with publication date: August 15, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.